Idiopathic trigeminal neuralgia still represents a problem regarding the choice of adeguate therapy. So, both medical and surgical options are proposed and used, but often the results are not significative. Medical therapy today offers AED drugs as gabapentin or uuse of botulinum toxine, as radiofrequency thermocoagulation is considered for surgical choice. A novel antiinflammatory drug, palmithoylethanolamide (PEA) is used successfully in prophylaxis treatment of neuropathic pain and in some headache syndromes. We used PEA in a series of cases of patients suffering from trigeminal pain in addition to pharmacological therapy already practiced. The results were good with 30 % of improvement on pain. This preliminary result, although the examined cases are few, encourages us to use PEA in idiopathic trigeminal neuralgia, recruiting a greater number of patients, to obtain more complete results.
Prof. Dr. Bilal BİLGİN